Dow Jones

40 211,72

0,00%

DAX

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
01/12/2010	14h00	Business Wire	Allos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/11/2010	14h00	Business Wire	New FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	21h10	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	21h05	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	21h00	Business Wire	Allos Therapeutics Reports Third Quarter 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/10/2010	22h00	Business Wire	Allos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
22/10/2010	23h21	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/10/2010	16h06	Dow Jones News	Allos Granted Orphan Status In Europe For Lymphoma Drug	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/10/2010	15h00	Business Wire	Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2010	14h19	Dow Jones News	Allos' Pralatrexate Outperforms Tarceva In Lung-Cancer Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2010	13h15	Business Wire	Allos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/10/2010	16h00	GlobeNewswire Inc.	Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing Bell	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/09/2010	22h14	Edgar (US Regulatory)	Amended Current report filing (8-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/09/2010	23h40	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (3/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/09/2010	15h00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/09/2010	19h29	Business Wire	Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/09/2010	23h50	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/09/2010	22h19	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/07/2010	22h17	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (S-8)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/07/2010	13h30	Business Wire	Allos Therapeutics Reports Second Quarter 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/07/2010	13h00	Business Wire	Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/07/2010	15h00	Business Wire	Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/06/2010	15h00	Business Wire	Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/06/2010	17h45	Business Wire	Allos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/06/2010	15h00	Business Wire	Allos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/06/2010	15h00	Business Wire	Allos Therapeutics to Present at Four Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/06/2010	15h00	Business Wire	Allos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/05/2010	15h00	Business Wire	Allos Therapeutics to Present at the Citi Investment Research Global Health Care Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
18/05/2010	14h52	Dow Jones News	Allos Gets Orphan-Drug Designation For Bladder Cancer Drug	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
18/05/2010	14h00	Business Wire	Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)